Advertisement

Understanding and modifying thrombotic risk in patients with myeloproliferative neoplasms

Published:January 07, 2023DOI:https://doi.org/10.1016/j.jjcc.2022.12.009
      We truly enjoyed reading the recently published paper by Leiva et al. [
      • Leiva O.
      • Jenkins A.
      • Rosovsky R.P.
      • Leaf R.K.
      • Goodarzi K.
      • Hobbs G.
      Predictors of increased risk of adverse cardiovascular outcomes among patients with myeloproliferative neoplasms and atrial fibrillation.
      ] who reported that the currently established CHA2DS2-VASC thrombotic risk score might suboptimally perform in patients with myeloproliferative neoplasms (MPN) having atrial fibrillation (AF). These findings are of high clinical importance and bring forward awareness on unique cardiovascular risks of MPN patients.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Journal of Cardiology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Leiva O.
        • Jenkins A.
        • Rosovsky R.P.
        • Leaf R.K.
        • Goodarzi K.
        • Hobbs G.
        Predictors of increased risk of adverse cardiovascular outcomes among patients with myeloproliferative neoplasms and atrial fibrillation.
        J Cardiol. 2022; (S0914-5087(22)00269-6) (Online ahead of print. [Elsevier: Please update])https://doi.org/10.1016/j.jjcc.2022.10.007
        • Lip G.Y.
        • Nieuwlaat R.
        • Pisters R.
        • Lane D.A.
        • Crijns H.J.
        Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the Euro Heart survey on atrial fibrillation.
        Chest. 2010; 137: 263-272
        • Krecak I.
        • Lucijanic M.
        • Verstovsek S.
        Advances in risk stratification and treatment of polycythemia vera and essential thrombocythemia.
        Curr Hemat Malig Rep. 2022; 17: 155-169
        • Krečak I.
        • Morić Perić M.
        • Zekanović I.
        • Holik H.
        • Coha B.
        • Gverić-Krečak V.
        • et al.
        No impact of the increased number of cardiovascular risk factors on thrombosis and survival in polycythemia vera.
        Oncol Res Treat. 2021; 44: 201-203
        • Lucijanic M.
        • Krecak I.
        • Soric E.
        • Sabljic A.
        • Galusic D.
        • Holik H.
        • et al.
        Patients with post polycythemia vera myelofibrosis might experience increased thrombotic risk in comparison to primary and post essential thrombocythemia myelofibrosis.
        Leuk Res. 2022; 119106905